Compare CYRX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | CYBN |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.7M | 416.1M |
| IPO Year | N/A | N/A |
| Metric | CYRX | CYBN |
|---|---|---|
| Price | $9.66 | $8.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $12.83 | ★ $74.50 |
| AVG Volume (30 Days) | 464.7K | ★ 919.5K |
| Earning Date | 11-04-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $243,795,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.26 | N/A |
| P/E Ratio | $7.60 | ★ N/A |
| Revenue Growth | ★ 41.27 | N/A |
| 52 Week Low | $4.58 | $4.81 |
| 52 Week High | $11.44 | $10.73 |
| Indicator | CYRX | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 67.63 |
| Support Level | $9.40 | $6.53 |
| Resistance Level | $9.95 | $9.12 |
| Average True Range (ATR) | 0.34 | 0.52 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 52.83 | 69.40 |
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.